HR10094

1) What happened: On August 13, 2026, Rep. Val Hoyle (D-OR) introduced HR10094, the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026. The bill was referred to the House Committee on Energy and Commerce, the primary committee for healthcare legislation. With 7 cosponsors, all Democrats, the bill is in early stage with no committee markup scheduled. 2) The money trail: The bill authorizes no specific funding — it is a regulatory mandate, not an appropriation. The mechanism forces price negotiation on drugs purchased through Medicare and Medicaid, directly reducing revenue for pharmaceutical companies. The Congressional Budget Office would score this as deficit reduction, not spending. 3) Convergence: No related signals or procurement data were provided. This bill stands alone as a single legislative signal. 4) Structural winners and losers: Losers are pharmaceutical companies with high Medicare Part D exposure ($LLY, ) and PBMs that profit from rebate spreads. Winners are taxpayers and federal budget — no public companies benefit directly. The bill's early stage and partisan sponsorship limit near-term market impact. 5) Timeline: The bill must pass committee markup, House floor vote, Senate companion bill, and Presidential signature. Given the 119th Congress is in its second year, the window for passage narrows. No Senate companion bill exists yet.